argenx SE or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Argenx SE and Amicus Therapeutics, Inc. have shown contrasting trends in their SG&A management from 2014 to 2023. Over this period, Amicus Therapeutics saw a steady increase in SG&A expenses, growing by approximately 1,230%, from $20 million in 2014 to $275 million in 2023. In contrast, Argenx SE's SG&A expenses skyrocketed by over 16,600%, from $4 million to $710 million. This dramatic rise reflects Argenx's aggressive expansion and investment in administrative capabilities. While both companies have increased their spending, the rate at which Argenx SE has done so is significantly higher, indicating a strategic focus on scaling operations. Investors and industry analysts should consider these trends when evaluating the companies' operational efficiencies and long-term strategies.